Cargando…
Peptide-based delivery of therapeutics in cancer treatment
Current delivery strategies for cancer therapeutics commonly cause significant systemic side effects due to required high doses of therapeutic, inefficient cellular uptake of drug, and poor cell selectivity. Peptide-based delivery systems have shown the ability to alleviate these issues and can sign...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010702/ https://www.ncbi.nlm.nih.gov/pubmed/35434595 http://dx.doi.org/10.1016/j.mtbio.2022.100248 |
_version_ | 1784687538511806464 |
---|---|
author | Samec, Timothy Boulos, Jessica Gilmore, Serena Hazelton, Anthony Alexander-Bryant, Angela |
author_facet | Samec, Timothy Boulos, Jessica Gilmore, Serena Hazelton, Anthony Alexander-Bryant, Angela |
author_sort | Samec, Timothy |
collection | PubMed |
description | Current delivery strategies for cancer therapeutics commonly cause significant systemic side effects due to required high doses of therapeutic, inefficient cellular uptake of drug, and poor cell selectivity. Peptide-based delivery systems have shown the ability to alleviate these issues and can significantly enhance therapeutic loading, delivery, and cancer targetability. Peptide systems can be tailor-made for specific cancer applications. This review describes three peptide classes, targeting, cell penetrating, and fusogenic peptides, as stand-alone nanoparticle systems, conjugations to nanoparticle systems, or as the therapeutic modality. Peptide nanoparticle design, characteristics, and applications are discussed as well as peptide applications in the clinical space. |
format | Online Article Text |
id | pubmed-9010702 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-90107022022-04-16 Peptide-based delivery of therapeutics in cancer treatment Samec, Timothy Boulos, Jessica Gilmore, Serena Hazelton, Anthony Alexander-Bryant, Angela Mater Today Bio Review Article Current delivery strategies for cancer therapeutics commonly cause significant systemic side effects due to required high doses of therapeutic, inefficient cellular uptake of drug, and poor cell selectivity. Peptide-based delivery systems have shown the ability to alleviate these issues and can significantly enhance therapeutic loading, delivery, and cancer targetability. Peptide systems can be tailor-made for specific cancer applications. This review describes three peptide classes, targeting, cell penetrating, and fusogenic peptides, as stand-alone nanoparticle systems, conjugations to nanoparticle systems, or as the therapeutic modality. Peptide nanoparticle design, characteristics, and applications are discussed as well as peptide applications in the clinical space. Elsevier 2022-03-30 /pmc/articles/PMC9010702/ /pubmed/35434595 http://dx.doi.org/10.1016/j.mtbio.2022.100248 Text en © 2022 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Samec, Timothy Boulos, Jessica Gilmore, Serena Hazelton, Anthony Alexander-Bryant, Angela Peptide-based delivery of therapeutics in cancer treatment |
title | Peptide-based delivery of therapeutics in cancer treatment |
title_full | Peptide-based delivery of therapeutics in cancer treatment |
title_fullStr | Peptide-based delivery of therapeutics in cancer treatment |
title_full_unstemmed | Peptide-based delivery of therapeutics in cancer treatment |
title_short | Peptide-based delivery of therapeutics in cancer treatment |
title_sort | peptide-based delivery of therapeutics in cancer treatment |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010702/ https://www.ncbi.nlm.nih.gov/pubmed/35434595 http://dx.doi.org/10.1016/j.mtbio.2022.100248 |
work_keys_str_mv | AT samectimothy peptidebaseddeliveryoftherapeuticsincancertreatment AT boulosjessica peptidebaseddeliveryoftherapeuticsincancertreatment AT gilmoreserena peptidebaseddeliveryoftherapeuticsincancertreatment AT hazeltonanthony peptidebaseddeliveryoftherapeuticsincancertreatment AT alexanderbryantangela peptidebaseddeliveryoftherapeuticsincancertreatment |